Disclosure Of Cash Flow Statement [Text Block]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Disclosure of cash flow statement [text block]
NOT 26
Description of accounting policy for determining components of cash and cash equivalents [text block]
Likvida medel  
Cash and cash equivalents if different from statement of financial position [abstract]
Cash and cash equivalents
3,510,000,000 SEK
3,033,000,000 SEK
1,277,000,000 SEK
Income taxes paid (refund) [abstract]
Income taxes paid (refund), classified as operating activities
3,000,000 SEK
1,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.